Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates

Journal of Clinical Microbiology

Volumn 44, Issue 9, 2006, Pages 3098-3104

  Jevitt, Laura A ^a   Thorne, Grace M ^b   Traczewski, Maria M ^c   Jones, Ronald N ^d   McGowan Jr , John E ^e   Tenover, Fred C ^a   Brown, Steven D ^c  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c CLINICAL MICROBIOLOGY INSTITUTE   (United States)

^d JMI LABORATORIES   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LIPOPEPTIDE; VANCOMYCIN;

ACCURACY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH MICRODILUTION; CORRELATION ANALYSIS; DIFFUSION; DILUTION; DISK DIFFUSION METHOD; DRUG INDICATION; ETEST METHOD; EVALUATION; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORGANIZATION; PRIORITY JOURNAL; RELIABILITY; STANDARD; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 33748786289     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00665-06     Document Type: Article

References (36)

1. Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, B. I. Eisenstein, and the Daptomycin 98-01 and 99-01 Investigations. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681.
2. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.
3. Chambers, H. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:178-182.
4. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; CLSI approved standard M100-S16. Clinical and Laboratory Standards Institute, Wayne, Pa.
5. Cui, L., E. Tominaga, H.-M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
6. Cunha, B. A. 2005. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin. Microbiol. Infect. 11:33-42.
7. Deresinski, S. 2005. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40:526-573.
8. Eliopoulos, G. M. 2003. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36:473-481.
9. Fluit, A. C., F. Schmitz, J. Verhoef, and D. Milatovic. 2004. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob. Agents Chemother. 48:1007-1011.
10. Fridkin, S. K. 2001. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. 32:108-115.
11. Friedman, L., J. D. Alder, and J. A. Silverman. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145.
12. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38:51-58.
13. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2001. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. J. Antimicrob. Chemother. 48:557-561.
14. Hayden, M. K., K. Rezai, R. A. Hayes, K. Lolans, J. P. Quinn, and R. A. Weinstein. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287.
15. Hsueh, P., W. H. Chen, L. J. Teng, and K. T. Luh. 2005. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int. J. Antimicrob. Agents 26:43-49.
16. Jevitt, L. A., A. J. Smith, P. P. Williams, P. M. Raney, J. E. McGowan, Jr., and F. C. Tenover. 2003. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb. Drug Resist. 9:298-306.
17. Johnson, A. P., S. Mushtaq, M. Warner, and D. M. Livermore. 2004. Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar. J. Antimicrob. Chemother. 53:860-862.
18. Johnson, A. P., S. Mushtaq, M. Warner, and D. M. Livermore. 2004. Activity of daptomycin against multi-resistant gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int. J. Antimicrob. Agents 24:315-319.
19. Jorgensen, J. H., and S. A. Crawford. 2006. Assessment of two commercial susceptibility test methods for determinant of daptomycin MICs. J. Clin. Microbiol. 44:2126-2129.
20. Lipsky, B. A., and U. Stoutenburgh. 2005. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother. 55:240-245.
21. Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060.
22. Munoz-Price, L. S., K. Lolans, and J. P. Quinn. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin. Infect. Dis. 41:565-566.
23. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agent. Approved guideline M26-A, vol. 19, no. 18. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
25. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
26. Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin- dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066.
27. Sabol, K., J. E. Patterson, J. S. Lewis II, A. Owens, J. Cadena, and J. H. Jorgensen. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 49: 1664-1665.
28. Safdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
29. Sakoulas, G., J. Alder, C. Thauvin-Eliopoulos, R. C. Moellering, Jr., and G. Eliopoulos. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.
30. Silverman, J. A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.
31. Smith, P. F., B. M. Booker, A. B. Ogundele, and P. Kelchin. 2005. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against gram-positive bacterial isolates from a large cancer center. Diagn. Microbiol. Infect. Dis. 52:255-259.
32. Snydman, D. R., N. V. Jacobus, L. A. McDermott, J. R. Lonks, and J. M. Boyce. 2000. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 44:3447-3450.
33. Steenbergen, J. N., J. Alder, G. M. Thorne, and F. P. Tally. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J. Antimicrob. Chemother. 55:283-288.
34. Streit, J. M., R. N. Jones, and H. S. Sader. 2004. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. J. Antimicrob. Chemother. 53:669-674.
35. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Characterization of a vancomycin-resistant clinical isolate of Staphylococcus aureus from Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.
36. Wise, R., J. M. Andrews, and J. P. Ashby. 2001. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J. Antimicrob. Chemother. 48:563-567.